One of America's 'most promising' HIV vaccine clinical trials fails
-
Last Update: 2020-07-07
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
According to the Science Times, on September 18th a disastrous test for the AIDS vaccine was announced as a failure of a clinical trial of one of the most promising AIDS vaccinesIn 2004, a team of Merck, the U.SNational Institute of
Allergy and Infectiousdiseases, and an academic institution called the HIV Vaccine Alliance began implementing the V520 global human trial, called Step, and on September 18, 2007, the three parties announced the suspension of the clinical trialA mid-term safety analysis of the vaccine's large clinical trial showed that the vaccine could neither protect volunteers from the deadly virus nor reduce the number of viruses in people infected with HIV, according to the latest issue of the American journal Science"This news is shocking, it destroys our hopes," said Peggy Johnston, director of the AIDS Vaccine Program at the National Institute
for Allergy and InfectiousDiseaseSarah Alexander, a spokeswoman for the AIDS Vaccine Trial Network, said it was a sad day for the pharmaceutical industryAnthony Forsyth, director of the National Institute for Allergy and InfectiousDisease, worries that the failure of the trial could spark a backlash across the pharmaceutical industry, which is already wary of investing in AIDS vaccines"The industry will scratch and say that we need more real scientific data before we put a lot of resources into it, " he said"
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
